Earnings call transcript: The Marzetti Company tops EPS in Q4 2026, revenue misses

The Marzetti Company reported fiscal Q4 adjusted EPS of $1.46 vs. $1.40 expected (+4.29%) while revenue missed at $465.0M vs. $479.0M (down 2.2% YoY; -2.91% vs forecast). Margins improved materially with gross margin up 220 bps (reported) and operating income up 48.2% on productivity savings, partially offsetting the top-line weakness and the discontinuation of temporary supply agreement sales. Management guided fiscal 2027 to mid-single-digit revenue growth with ~100 bps consolidated gross margin expansion, but flagged a Cyclospora outbreak headwind of ~250 bps to first-quarter fiscal 2027 net sales and expects operating income down ~15% in Q1.

Analysis

MZTI is a classic “good company, noisy quarter” setup: the market will likely focus on the revenue miss and outbreak-driven Q1 air-pocket, but the more important signal is that the business is still converting pricing, hedging and network changes into margin despite softer mix. That matters because in packaged foods, sustained gross-margin expansion usually precedes multiple re-rating before top-line acceleration fully shows up.

The bigger second-order winner is TXRH and the broader licensed-restaurant franchise pipeline: if MZTI can keep turning restaurant-branded products into higher household penetration through WMT and club, it lowers dependence on the slower salad/dressing pool and creates a more durable shelf-reset machine. The risk is that this channel strategy becomes crowded; if consumers keep trading down, retailers may substitute toward private label or simpler condiment sets, which would cap both velocity and margin mix.

Near term, the outbreak is the key catalyst and also the key falsifier. If the demand hit is confined to one quarter and the company re-accelerates in 2H as new items reset, the stock can work off of earnings power rather than sales momentum; if management has to take down FY27 gross-margin assumptions by even 50-100 bps, the multiple should compress again. Over 6-18 months, the question is whether Bachan’s and the Texas Roadhouse platform can create enough scale to offset structural softness in dressings and keep SG&A leverage intact.

Key Decisions for Investors

• Long MZTI on pullbacks over the next 2-4 weeks; favor entry after the first post-call digestion period, with the thesis that the market is over-discounting a temporary Q1 demand shock relative to FY27 margin durability. Falsify if Q1 gross margin fails to stabilize or FY27 margin expansion is cut below ~50 bps.
• Pair trade: long MZTI / short a packaged-food or condiment peer exposed to slower private-label competition and less mix improvement, using the next 1-3 months as the catalyst window. Risk/reward favors the leg with visible pricing power and cost savings versus the one with only volume exposure.
• Add TXRH as a smaller long-only watch item rather than a full trade; the value here is indirect distribution optionality through WMT and club, not immediate earnings impact. Use it as a channel proxy if scanner data confirms sustained velocity rather than one-off rollout gains.
• Avoid chasing after the initial relief rally; the better risk/reward is to wait for confirmation that the Cyclospora drag normalizes within the modeled 1-2 quarter window. If the disruption bleeds into the back half, the stock deserves de-rating rather than multiple expansion.
• Set an alert on MZTI guidance updates: if management reiterates mid-single-digit revenue growth and ~100 bps gross-margin expansion at the next update, that would support a re-rating; if not, reduce exposure ahead of the next print.